About Metalloreductase STEAP4
Metalloreductase STEAP4 (STEAP4) is a protein
from Homo sapiens identified by UniProt accession
Q687X5, 459 residues long.
MolForge cross-references it against 0 known binders and
145 disease associations.
Target properties
| Protein name | Metalloreductase STEAP4 |
| UniProt accession | Q687X5 |
| Gene | STEAP4 |
| Organism | Homo sapiens |
| Length | 459 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (145)
Diseases linked to this target (Open Targets).
- hepatocellular carcinoma · score 0.11
- neoplasm · score 0.09
- breast cancer · score 0.08
- experimental autoimmune encephalomyelitis · score 0.07
- colorectal carcinoma · score 0.07
- gonorrhea · score 0.07
- Rheumatoid arthritis · score 0.07
- pulmonary arterial hypertension · score 0.07
- adolescent idiopathic scoliosis · score 0.07
- rheumatoid arthritis · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q687X5-F1 | alphafold | PREDICTED | 90.93 | — |
Amino-acid sequence (459 residues)
MEKTCIDALP LTMNSSEKQE TVCIFGTGDF GRSLGLKMLQ CGYSVVFGSR NPQKTTLLPS GAEVLSYSEA AKKSGIIIIA IHREHYDFLT ELTEVLNGKI LVDISNNLKI NQYPESNAEY LAHLVPGAHV VKAFNTISAW ALQSGALDAS RQVFVCGNDS KAKQRVMDIV RNLGLTPMDQ GSLMAAKEIE KYPLQLFPMW RFPFYLSAVL CVFLFFYCVI RDVIYPYVYE KKDNTFRMAI SIPNRIFPIT ALTLLALVYL PGVIAAILQL YRGTKYRRFP DWLDHWMLCR KQLGLVALGF AFLHVLYTLV IPIRYYVRWR LGNLTVTQAI LKKENPFSTS SAWLSDSYVA LGILGFFLFV LLGITSLPSV SNAVNWREFR FVQSKLGYLT LILCTAHTLV YGGKRFLSPS NLRWYLPAAY VLGLIIPCTV LVIKFVLIMP CVDNTLTRIR QGWERNSKH
Explore Metalloreductase STEAP4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets